Healthlead PCL (BKK:HL) EBIT: ฿113 Mil (TTM As of Mar. 2026)


BKK:HL Healthlead PCL BKK:HL
76 GF Score
Price ฿5.50
GF Value ฿10.82
Valuation Significantly Undervalued
! 3 Warning Signs
View Full Analysis

What is Healthlead PCL EBIT?

Healthlead PCL BKK:HL -1.79% 76 EBIT is ฿113 Mil as of Mar. 2026. GuruFocus rates BKK:HL with a GF Score™ of 76/100 and a GF Value™ of ฿10.82 (Significantly Undervalued). The stock has 3 warning signs investors should review.

Healthlead PCL's earnings before interest and taxes (EBIT) for the three months ended in Mar. 2026 was ฿27 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Mar. 2026 was ฿113 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Healthlead PCL's annualized ROC % for the quarter that ended in Mar. 2026 was 11.28%. Healthlead PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 16.73%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Healthlead PCL's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was 9.49%.


Healthlead PCL  (BKK:HL) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Healthlead PCL's annualized ROC % for the quarter that ended in Mar. 2026 is calculated as:

ROC % (Q: Mar. 2026 )
=NOPAT/Average Invested Capital
=Operating Income * ( 1 - Tax Rate % )/( (Invested Capital (Q: Dec. 2025 ) + Invested Capital (Q: Mar. 2026 ))/ count )
=106.764 * ( 1 - 18.94% )/( (765.368 + 768.542)/ 2 )
=86.5428984/766.955
=11.28 %

where

Invested Capital(Q: Dec. 2025 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1535.908 - 221.209 - ( 549.331 - max(0, 268.692 - 912.871+549.331))
=765.368

Invested Capital(Q: Mar. 2026 )
=Total Assets - Accounts Payable & Accrued Expense - Excess Cash
=Total Assets - Accounts Payable & Accrued Expense - ( Cash, Cash Equivalents, Marketable Securities - max(0, Total Current Liabilities - Total Current Assets+Cash, Cash Equivalents, Marketable Securities))
=1562.618 - 262.804 - ( 531.272 - max(0, 311.514 - 945.261+531.272))
=768.542

Note: The Operating Income data used here is four times the quarterly (Mar. 2026) data.

2. Joel Greenblatt's definition of Return on Capital:

Healthlead PCL's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 is calculated as:

ROC (Joel Greenblatt) %(Q: Mar. 2026 )
=EBIT/Average of (Net fixed Assets + Net Working Capital)
=EBIT/Average of (Property, Plant and Equipment+Net Working Capital)
     Q: Dec. 2025  Q: Mar. 2026
=EBIT/( ( (Property, Plant and Equipment + Net Working Capital) + (Property, Plant and Equipment + Net Working Capital) )/ count )
=109.42/( ( (551.461 + max(95.644, 0)) + (544.606 + max(116.39, 0)) )/ 2 )
=109.42/( ( 647.105 + 660.996 )/ 2 )
=109.42/654.0505
=16.73 %

where Working Capital is:

Working Capital(Q: Dec. 2025 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(5.628 + 308.707 + 5.331) - (221.209 + 1.2 + 1.613)
=95.644

Working Capital(Q: Mar. 2026 )
=(Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Defer. Rev. + Other Current Liabilities)
=(6.568 + 370.332 + 4.9649999999999) - (262.804 + 1.392 + 1.2790000000001)
=116.39

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Healthlead PCL's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %=EBIT (TTM)/Enterprise Value (Q: Mar. 2026 )
=112.738/1187.973
=9.49 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Healthlead PCL EBIT Related Terms


Healthlead PCL EBIT Historical Data

* Premium members only.

The historical data trend for Healthlead PCL's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Healthlead PCL EBIT Chart

Healthlead PCL Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
EBIT
Get a 7-Day Free Trial 102.68 148.56 103.02 110.07 115.09

Healthlead PCL Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
EBIT Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 29.71 25.47 20.32 39.60 27.36

Healthlead PCL EBIT Competitor Comparison

For the Pharmaceutical Retailers subindustry, Healthlead PCL's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Healthlead PCL EV-to-EBIT vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Healthlead PCL's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Healthlead PCL's EV-to-EBIT falls into.


BKK:HL
76GF Score
Healthlead PCL BKK:HL
EBIT is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Healthlead PCL EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ฿113 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EBIT →
What does a EBIT of ฿113 Mil mean?
Healthlead PCL (BKK:HL) has a EBIT of ฿113 Mil as of Mar. 2026. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Healthlead PCL.
Is Healthlead PCL's EBIT too high?
Healthlead PCL's current EBIT is ฿113 Mil. Overall, Healthlead PCL has a GF Score™ of 76/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Healthlead PCL's EBIT compare to competitors?
Healthlead PCL's EBIT of ฿113 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT for a Healthcare Providers & Services company?
A good EBIT depends on the Healthcare Providers & Services industry context. However, EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT mean?
A high EBIT can signal that a stock is expensive relative to its fundamentals. Earnings before interest and taxes is the difference between operating revenue and operating expenses. View historical data on Healthlead PCL. Healthlead PCL's current EBIT is ฿113 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Healthlead PCL stock overvalued right now?
Based on GuruFocus' analysis, Healthlead PCL (BKK:HL) is currently considered Significantly Undervalued. The stock's GF Value™ is ฿10.82, compared to a current price of ฿5.50 — trading 49.2% below its estimated fair value. The current EBIT is ฿113 Mil. Healthlead PCL's overall GF Score™ is 76/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT calculated?
EBIT is calculated from a company's financial statements. For Healthlead PCL (BKK:HL), the current EBIT is ฿113 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Healthlead PCL (BKK:HL) Overvalued in 2026?

Based on GuruFocus' analysis, Healthlead PCL stock appears to be undervalued. The current stock price of ฿5.50 is trading 49.2% below its estimated GF Value™ of ฿10.82. GuruFocus considers Healthlead PCL to be Significantly Undervalued.

Key valuation signals for BKK:HL:

  • EBIT: ฿113 Mil
  • GF Value™: ฿10.82 vs. price of ฿5.50 (49.2% below fair value)
  • GF Score™: 76/100 with 3 warning signs

No single metric tells the full story. See the BKK:HL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Healthlead PCL Business Description

Address 99/4 Moo 10, Bang Muang Sub-District, Bang-Yai District, Nonthaburi, THA, 11140
Healthlead PCL is a holding company. Along with its subsidiaries, it operates a pharmacy business under iCare, Pharmax, vitaminclub, and Super Drug brands, distributing medicines, medical supplies, cosmeceuticals, dietary supplements, medical devices, and other healthcare products. Additionally, it is involved in co-inventing and co-developing healthcare products in collaboration with external research teams and contract manufacturers, producing and distributing its own branded products. Geographically, the group operates only in Thailand.
76GF Score

Get the complete analysis for BKK:HL

EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

฿5.50
Price
฿10.82
GF Value